Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Therapy Name||A-966492 + Radiotherapy + Topotecan|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|A-966492||A966492||PARP Inhibitor (Pan) 22||A-966492 is an inhibitor of PARP1 and PARP2, potentially resulting in increased sensitivity of tumor cells to DNA damaging agents (PMID: 20337371, PMID: 28797568).|
|Topotecan||Hycamtin||Topotecan Hcl||Topotecan binds to topoisomerase I and stablizes complexes with DNA, resulting in decreased repair of DNA single-strand breaks, and potentially leading to cell death (NCI Drug Dictionary).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||glioblastoma||not applicable||A-966492 + Radiotherapy + Topotecan||Preclinical - Cell culture||Actionable||In a preclinical study, the combination treatment of A-966492 and Hycamtin (topotecan) resulted in enhanced radiosensitivity in glioblastoma cells in culture, demonstrating a greater reduction in cell survival (PMID: 28797568).||28797568|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|